NCT06753565RecruitingPhase 2
L-carnitine Supplementation in Rheumatoid Arthritis Patients
Effect of L-carnitine Supplementation on Disease Activity in Rheumatoid Arthritis Patients
Source: ClinicalTrials.gov · Last updated 7 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 26 Nov 2024
- Start date
- Dec 2024
- Primary completion date
- Jun 2025
- Lead sponsor
- German University in Cairo
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT06753565
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From Dec 2024 to the primary completion date, Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with any active infection or concurrent malignancy
- patients currently taking drugs that could interact with carnitine like: warfarin
Other illness
- patients with uncontrolled medical conditions or other rheumatic diseases
Lab values
- patients with liver dysfunction (\>1.5x the upper limit of normal value for ALT \& AST)
- Patients with kidney dysfunction (serum creatinine more than 1.2 mg/dl)
Other
- pregnant or lactating female
Who the study is looking for
- age between 18-60 years old
- diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months
- enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study
- active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2)
- patient or legal representative should sign informed consent
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Demerdash hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.